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DOI 10.1016/j.ccr.2012.03.040SUMMARYTetraspanins are commonly believed to act only as ‘‘molecular facilitators,’’ with no direct role in signal trans-
duction. We herein demonstrate that upon ligation, CD37, a tetraspanin molecule expressed on mature
normal and transformed B cells, becomes tyrosine phosphorylated, associates with proximal signalingmole-
cules, and initiates a cascade of events leading to apoptosis. Moreover, we have identified two tyrosine resi-
dues with opposing regulatory functions: one lies in the N-terminal domain of CD37 in a predicted ‘‘ITIM-like’’
motif and mediates SHP1-dependent death, whereas the second lies in a predicted ‘‘ITAM motif’’ in the
C-terminal domain of CD37 and counteracts death signals by mediating phosphatidylinositol 3-kinase-
dependent survival.INTRODUCTION
It is generally assumed that tetraspanins are not directly involved
in signal transduction, becauseof the lack of embedded signaling
motifs, and that they instead serve as ‘‘molecular facilitators’’ of
signal transduction (Maecker et al., 1997). For instance, tetraspa-
nins such as CD53 and CD63 associate with a protein tyrosine
phosphatase in rat lymph node cells and a rat mast cell line,
respectively (Carmo and Wright, 1995), whereas CD9-mediated
signaling in platelets involves activation of the protein tyrosineSignificance
The signaling role of CD37 in normal and transformed B cells h
tified a unique function of CD37 as a death receptor in B cells.
directlymediate dual signal transduction through the C- andN-
CD37 exert completely different functions by concurrently acti
ties for immunotherapy directed at CD37 cell death-mediated s
peptides or kinase inhibitors that target the C-terminal activat
694 Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc.kinase p72SYK (Ozaki et al., 1995). Tetraspanins can also asso-
ciate noncovalently with other immune molecules—for example,
CD9 and CD63 with integrins (Berditchevski et al., 1995; Rubin-
stein et al., 1994), CD81 with CD19/CD21 on B cells (Matsumoto
et al., 1993), and with CD4 or CD8 on T cells (Imai and Yoshie,
1993)—suggesting that signaling through tetraspanins, possibly
following binding to a yet-unidentified ligand, may regulate the
functions of key players in immune recognition.
CD37 is a member of the transmembrane 4 superfamily
(TM4SF) of tetraspanin proteins, which have four potentialas not been characterized. Our extensive studies have iden-
We have demonstrated that CD37 is a tetraspanin that can
terminal domain. The finding that two independent regions of
vating cell death and survival pathways opens up opportuni-
ignaling in combination with development of small inhibitory
ion domain to maximize cell death.
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CD37 Regulates Cell Survival in B Cellsmembrane-spanning regions (Horejsı´ and Vlcek, 1991; Wright
and Tomlinson, 1994). CD37 is expressed in developing B cells
from pre-B to peripheral mature B cell stages, but not plasma
cells. T cells, monocytes, and natural killer (NK) cells express
very low levels of CD37 (Schwartz-Albiez et al., 1988), and it is
absent on platelets and erythrocytes (van Spriel et al., 2004).
CD37 forms protein complexes with CD53, CD81, CD82, and
class II glycoprotein on the B cell surface that may represent
an ion channel or a transporter (Angelisova´ et al., 1994). More-
over, CD37 is expressed in B cell endosomes and exosomes,
reflecting possible involvement in intracellular trafficking or
antigen presentation. Targeted inactivation of CD37 in mice
revealed no changes in the development of lymphoid organs,
but reduced IgG1 levels and alteration of response to T cell–
dependent antigens, indicating a possible role for CD37 in
T cell–B cell interaction (Knobeloch et al., 2000). Although the
precise function of CD37 and its ligand remains unknown, it
has been proposed to have a role in signal transduction path-
ways that affects cell development, activation, and motility
(Wright and Tomlinson, 1994). The direct involvement of CD37
in signaling seems unlikely because of short cytoplasmic tails
(8 to 14 amino acids) that lack canonic signaling motifs.
Given itsBcell-selective expression,CD37 represents a candi-
date therapeutic target for B cell malignancies, such as chronic
lymphocytic leukemia (CLL). Several peptides, including anti-
CD37 SMIP (monospecific protein therapeutic, also referred
to as SMIP-016), have been shown to induce rapid and potent
in vitro direct tumoricidal activity in lymphoma/leukemia cells
(Zhao et al., 2007). TRU-016, a humanized SMIP-016, is currently
in a phase 1 clinical trial for relapsed CLL and small lymphocytic
lymphoma (SLL) (http://www.clinicaltrials.gov/). Other CD37 tar-
geted antibodies are currently in early clinical development (Hal-
lek et al., 2008; Heider et al., 2011). However, themolecular basis
of CD37-mediated cell death is unknown.
RESULTS
Identification of Tyrosine-Phosphorylated Proteins
following CD37 Ligation Using Nano-LC-MS/MS
Expression of CD37 on CLL cells is variable, with significantly
higher expression on IgVH-mutated versus IgVH-unmutated
cells (see Figure S1A available online). Death induced by
SMIP-016 is dose and time dependent (Zhao et al., 2007) and
correlates with CD37 antigen density (Figure S1B), but not prog-
nostic factors associated with poor outcome in CLL (Figures
S1C–S1E). How CD37 ligation induces apoptosis is unknown.
Treatment of CLL cells with SMIP-016 induces tyrosine phos-
phorylation of multiple proteins (Figure 1A), as indicated
by immunoblot using anti-phosphotyrosine antibody 4G10
(Zhao et al., 2007). To identify these tyrosine-phosphorylated
proteins, we undertook a proteomic approach. CLL cells were
treated with SMIP-016 or trastuzumab, which does not bind
CLL cells because these cells do not express HER2. Trastuzu-
mab therefore is a good negative control to rule out potential
Fcg receptor-mediated signaling. The lysates were separated
by SDS-PAGE following immunoprecipitation with 4G10, and
the immunoprecipitated proteins were recovered by in-gel
digestion. Following a phosphopeptide enrichment step,
peptides were analyzed by LC-MS/MS.Independent experiments from five patients reproducibly
identified several tyrosine-phosphorylated proteins, including
protein phosphatase non-receptor-type 6 (PTPN6/SHP1) and
the SRC family kinase LYN. SMIP-016-induced tyrosine
phosphorylation of SHP1 and LYN was confirmed by immuno-
precipitation using 4G10, followed by anti-SHP1 or anti-LYN
immunoblot analysis, and vice versa (Figure S1F and data not
shown). Tyrosine phosphorylation of SHP1 (Yi et al., 1992) has
been implicated in cell growth regulation, and loss of SHP1
in leukemia and other malignancies suggest it to be a tumor
suppressor (Wu et al., 2003). We first assessed SHP1, SHP2,
and PP2A protein levels in CLL (Figure S1G) and found variable
expression of these proteins. To determine whether phosphory-
lation of SHP1 alters its phosphatase activity, we immunoprecip-
itated SHP1 from CLL patient cells treated with either trastuzu-
mab or SMIP-016 and assessed its tyrosine phosphatase
activity. SHP1 purified from SMIP-016-treated cells exhibited
increased enzymatic activity relative to trastuzumab control
(Figure 1B). SHP1 downregulation by siRNA resulted in almost
complete loss of SMIP-016-induced cytotoxicity compared
to nonsense siRNA (Figure 1C), supporting that SHP1 is
involved in CD37-mediated cell death, which contrasts with
SHP1-independent death induced by CD20 ligation (Kheirallah
et al., 2010).
We also identified CD37, SHIP-1, and SYK in the LC-MS/MS
analysis. CD37 has three tyrosine residues in its cytoplasmic
tail. Detailed sequence analysis shows one of them at the
N-terminal (N-t) domain within a predicted weak immune tyro-
sine-based inhibitory motif (ITIM) and the other two at the
C-terminal (C-t) domain, with one located in an YxxL context
within a single immune tyrosine-based activation motif (ITAM)
(Figure 1D). An ITIM is a conserved sequence of amino acids
(S/I/V/LxYxxI/V/L) that is found in the cytoplasmic tails of many
inhibitory receptors of the immune system. Interaction of ITIM-
bearing receptors with their ligands results in SRC family
kinase-mediated tyrosine phosphorylation of the ITIM motif
and recruitment of other enzymes, such as SHP1 and SHP2, or
SHIP-1, an inositol phosphatase, that decrease the activation
of cell signaling molecules. Similarly, the two tyrosine residues
contained within the ITAM motif (defined by a consensus
sequence: YxxI/Lx(6-12)YxxI/L, where x represents any amino
acid) are typically phosphorylated by the SRC family of tyrosine
kinases. This results in recruitment of SYK, and initiation of
downstream cell activation signals leading to proliferation. The
observations that (1) LYN and SHP1 are phosphorylated upon
CD37 ligation, (2) SHP1 is directly involved in CD37-mediated
cell death, and (3) SHP1 is known to bind to weak ITIM sug-
gested that the ITIM-like motif in CD37 N-t might be functional.
We confirmed that, in CLL cells stimulated with SMIP-016,
CD37 was tyrosine phosphorylated and associated with both
SHP1 and LYN (Figures 1E and 1F). Thus, CD37 engages the
negative signaling effectors SHP1 and LYN when tyrosine phos-
phorylated, consistent with the presence of an ITIM.
SMIP-016-Induced Apoptosis Requires Translocation
of CD37 into the Lipid Rafts
Lipid rafts are plasma membrane microdomains enriched in
gangliosides (glycosphingolipids) and cholesterol that are
involved in many signal transduction processes. For instance,Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc. 695
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Figure 1. CD37 Ligation Induces Tyrosine Phosphorylation of SHP1, LYN, and CD37
(A) Lysates from trastuzumab+aFc- or SMIP-016+aFc-treated (15 min) CLL cells were analyzed by 2-D electrophoresis. A representative experiment is shown.
M, molecular weight marker.
(B and C) SHP1 phosphatase activity of trastuzumab+aFc- or SMIP-016+aFc-treated cells (15 min) (B). Each symbol represents a different CLL patient sample,
and red line represents the average (C) SMIP-016-induced cytotoxicity (24 hr) of untransfected CLL cells (U) or CLL cells transfected with SHP1 siRNA or
a nonsense siRNA (NS), as measured by annexin-V/PI staining (mean ± SD, n = 6). The immunoblot shows protein knockdown by siRNA in a representative
sample.
(D) Amino acid sequence of human CD37 protein. Underscored text, intracellular regions; blue box, ITIM-like motif; green box, ITAM motif; red circles, cytosolic
tyrosine residues.
(E) Lysates from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CLL cells (15 min) were immunoprecipitated with anti-CD37 followed by CD37 or
4G10 immunoblot. Two representative samples out of a total of three are shown.
(F) Lysates from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CLL cells (15 min) were immunoprecipitated using anti-SHP1 or anti-LYN followed by
SHP1, LYN, or CD37 immunoblot. Representative of four patient samples is shown.
(G) Distributions of CD37, pLYN pSHP1, and pSRC in the non-raft (NR) and lipid raft (R) fractions prepared from CLL cells treated with trastuzumab+aFc (T) or
SMIP-016+aFc (S) (15 min). A representative experiment is shown.
See also Figure S1.
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Figure 2. Generation of CD37+FLAG 697Cell
Line
(A and B) Expression of CD37 in CD37+FLAG 697
cells measured by flow cytometry (A) and immu-
noblot (B) with or without doxycycline (Doxy)
stimulation (24 hr); 697 cells expressing a reverse
complement sequence (RC) of CD37 were used as
a negative control. NS, nonspecific bands.
(C) CD37+FLAG 697 cells were treated for 24 hr
with aFc, trastuzumab+aFc (T), SMIP-016+aFc
(S), or anti-CD19+aFc, and cytotoxicity was
measured by annexin-V/PI (mean ± SD, n = 8).
(D) Lysates derived from trastuzumab+aFc-
treated (T) or SMIP-016+aFc-treated (S) CD37+
FLAG 697 cells (15 min) were analyzed by immu-
noblot using 4G10 antibody. Representative of
three experiments is shown.
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CD37 Regulates Cell Survival in B Cellsapoptosis induced by rituximab (anti-CD20) requires transloca-
tion of CD20 into lipid rafts where it interacts and activates
protein tyrosine kinases LYN, FYN, and LCK (Janas et al.,
2005; Semac et al., 2003). Upon cross-ligation with SMIP-016,
but not trastuzumab, CD37 became associated within
membrane lipid rafts along with pSHP1, pLYN, and pSRC (Fig-
ure 1G). GAPDH serves as a negative control for the isolation
of detergent insoluble membranes, whereas total LYN, SHP1,
and SRC serve as a positive control because they have been
shown to normally reside in lipid rafts (Mone et al., 2004). The
purity of the fractions was confirmed using cholera toxin B
subunit-HRP (CT-B) that binds to GM-1, a specific marker of
membrane lipid raft (Figure S1I). Cytochalasins inhibit F-actin
polymerization, interfere with lipid raft aggregation, and inhibit
anti-HLA-DR and anti-CD47 antibody-induced lymphocyte cell
death (Truman et al., 1994). Similarly, cytochalasin D (CytD) or
latrunculin B (LatB) pretreatment of CLL cells reduced SMIP-
016-inducedcell death (FigureS1J) andaggregation (FigureS1K).
Generation of CD37+FLAG 697 pTet-on Cell Lines
To study in more detail the biology of CD37, we created an
inducible CD37+FLAG 697 cell line, a derivative of the CD37-
negative 697 human acute lymphoblastic leukemia (ALL) cell
line, that expresses CD37 upon induction with doxycycline
(Figures 2A and 2B). Consistent with the signaling competence
of the transfected CD37, treatment of CD37+FLAG 697 cells
with SMIP-016 significantly induced cytotoxicity (Figure 2C) as
well as tyrosine phosphorylation of multiple proteins (Figure 2D).
Anti-CD19 was used as a control, because CD19 levels are not
affected by doxycycline treatment.
CD37 Is Tyrosine Phosphorylated upon Ligation
by SMIP-016
To study phosphorylation events, protein lysates from SMIP-
016-treated CD37+FLAG 697 cells were immunoprecipitated
with 4G10 followed by immunoblot analysis using antibodiesCancer Cell 21, 694–specific to proximal signaling targets.
These studies identified tyrosine phos-
phorylation of CD37 (as detected with
anti-FLAG), LYN, SHP1, and SYK,
following SMIP-016 treatment (Figure 3A).Next, 4G10 immunoprecipitates from SMIP-016-treated CD37+
FLAG 697 cells were separated by SDS-PAGE and were sub-
jected to in-gel trypsin digestion followed by a phosphopeptide
enrichment step. Proteomics analysis was then performed by
neutral loss tandem mass spectrometry on a Thermo Scientific
LTQ Orbitrap XL. Five unique peptides of CD37 isoforms A and
B were found in SMIP-016-treated but not trastuzumab-treated
samples (Figure 3B), with 30% of the sequence covered
including phosphorylation at Tyr274 (C-terminal region). No alter-
native proteins were identified from the 37 kDa region of the gel.
The presence of CD37 in these immunoprecipitates was inde-
pendently verified by anti-FLAG immunoblot (data not shown).
Furthermore, lysates from SMIP-016 or trastuzumab-treated
cells were immunoprecipitated with anti-FLAG antibody and
analyzed by 4G10 immunoblot showing the presence of
a band of approximately 37 kDa (Figures 3C and 3D), in the
SMIP-016 treated lysates, that was abolished by treatment
with l-protein phosphatase (Figure 3D). Coimmunoprecipitation
studies using CD37+FLAG 697 cells were conducted to confirm
that CD37 associates with LYN, SHP1, and SYK upon ligation
with SMIP-016 (Figure 3E) and that LYN and SYK were also
phosphorylated (Figure 3F), similar to CLL cells. Initial attempts
to downmodulate SHP1 in this cell line model using siRNA
were unsuccessful, prompting creation of a 697 cell line with
stable expression of CD37 and doxycycline-inducible expres-
sion of a short hairpin (sh) RNA for SHP1 (shSHP1). In these cells,
downmodulation of SHP1 (by 120 hr) resulted in a reduction of
SMIP-016-mediated cell death, consistent with the data in
primary CLL cells (Figure 3G).
CD37 Possesses Dual Inhibitory and Activation
Signaling Functions
To study the relevance of tyrosine phosphorylation in CD37-
mediated killing, 697 cell lines carrying mutations or deletions
of tyrosine residues in the cytosolic regions of the CD37 mole-
cule were generated (Figure 4A). The deletion of Tyr274 or its708, May 15, 2012 ª2012 Elsevier Inc. 697
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Figure 3. CD37 Is Tyrosine Phosphorylated upon Ligation by SMIP-016
(A) Lysates derived from CD37+FLAG 697 cells (with or without doxycycline) treated with aFc (a), trastuzumab +aFc (T), or SMIP-016+aFc (S) (15 min) were
immunoprecipitatedwith 4G10, followed by immunoblot analysis using antibodies specific to SHP1, SYK, LYN, andCD37. Representative of three experiments is
shown. Doxycycline-induced expression of CD37 was verified by anti-FLAG immunoblot (bottom panel).
(B) Sequence coverage of CD37 by phosphoproteomic analysis in SMIP-016-treated CD37+FLAG 697 cells as identified by the MassMatrix software.
(C) Lysates derived from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CD37+FLAG 697 cells (15 min) were immunoprecipitated with anti-FLAG,
followed by 4G10 immunoblot.
(D) Anti-FLAG-immunoprecipitated lysates from C were treated with l-protein phosphatase (l-ppase) followed by 4G10 immunoblot.
(E) Lysates derived from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CD37+FLAG 697 cells (15 min) were immunoprecipitated with anti-
FLAG, -SHP1, -SYK, or -LYN antibody followed by immunoblot with the indicated antibodies. Results from two different WT cell lines are shown.
(F) Lysates from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) (15 min) WT, C-t(-), Tyr13-Phe, or Tyr13-Phe/C-t(-) cell lines were immunoprecipitated
using anti-CD37, followed by pSYK and pLYN immunoblot.
(G) SMIP-016-induced cytotoxicity of cells with doxycycline-induced downregulation of SHP1 measured by annexin-V/PI staining. Mean ± SD, n = 3.
T, trastuzumab+aFc; S, SMIP-016+aFc. The SHP1 protein level is determined using immunoblot. A representative immunoblot is shown.
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CD37 Regulates Cell Survival in B Cellsmutation to phenylalanine (Phe) did not affect surface expression
of CD37 but significantly increased the cytotoxic effect of SMIP-
016 (Figure 4B). Deletion of the entire C-t cytosolic portion of
CD37, which includes Tyr274 and Tyr280 (Figure 4A), also did
not affect surface expression of CD37 but again significantly
enhanced the cytotoxic effect of SMIP-016 (Figure 4C) consis-
tent with a regulatory function of this region in CD37-mediated
cell death. To test the relevance of Tyr13 in the putative N-t
ITIM domain, 697 cell lines expressing an N-t truncated CD37
[N-t(-)], a single deletion mutant [Tyr13(-)], or a Tyr13-Phe mutant
were generated (Figure 4A). In the N-t(-) and Tyr13(-) cells, no
surface CD37 was observed, although CD37 mRNA was still
produced and translated (data not shown).The lack of surface
expression of CD37 therefore could be attributed to the pres-
ence of a membrane localization signal in the deleted portions
of the molecule. In contrast, the substitution of Tyr13 to Phe did
not affect surface expression of CD37 but significantly reduced
the cytotoxic effect of SMIP-016 (Figure 4D), indicating that
this region positively regulates CD37-mediated cell death,
consistent with an ITIM function for this domain. A similar death
pattern among the cell lines was also observed for NK cell-medi-
ated antibody-dependent cellular cytotoxicity (ADCC) (Fig-
ure S2A), further demonstrating the physiologic relevance of
CD37 phosphorylation at the ITIM and ITAM sites.
The effects of N-t and C-t tyrosine deletions on protein-protein
interactions and tyrosine phosphorylation were also studied.
SMIP-016 treatment of cells induced phosphorylation of both
the C-t-deleted and the wild-type (WT) CD37 (Figure 4E) that
was sensitive to l-protein phosphatase treatment (Figure 4F),
but the amount of phosphorylation was visibly higher for the
C-t-deleted CD37, suggesting that the C-t domain interferes
with phosphorylation of the N-t. Furthermore, the lack of the
C-t region did not prevent CD37 association with SHP1, LYN,
and SYK (Figure 4G) or coassociation of LYN and SHP1 (Fig-
ure S2B). In contrast, the replacement of Tyr13 with Phe notably
reduced SMIP-016-induced CD37 phosphorylation (Figure 4H)
and prevented association of SHP1 and LYN with CD37 (Fig-
ure 4I) as well as each other (Figure S2B). Together, these data
suggest that Tyr13 acts in the context of an ITIMmotif, phosphor-
ylation of which mediates apoptosis through recruitment and
activation of LYN and SHP1. Importantly, the Tyr13-Phe/C-t(-)
double mutant CD37 was not phosphorylated when cells were
treated with SMIP-016 (Figure 4H). Furthermore, consistent
with our previous report (Zhao et al., 2007), herbimycin treatment
of the WT and the C-t(-) cell lines prevented cell death (data not
shown) and SHP1-CD37 association in both cell lines (Figure 4J).
To further demonstrate the phosphorylation and ITIM function of
CD37 at the N-t region, we performed a GST pull-down experi-
ment based on the assumption that SH2 domains of SHP1 can
bind only to phosphorylated ITIM domains. Lysates derived
from 697 cells expressing various forms of CD37 and treated
with trastuzumab or SMIP-016 were incubated with GST-
SHP1(SH2)N-t, GST-SHP1(SH2)C-t, or GST-SHIP(SH2) fusion
proteins, and protein-protein complexes were then purified
using glutathione agarose beads (GSH beads). The results
show that both GST-SHP1(SH2)N-t and GST-SHP1(SH2)C-t
pulled down the WT and the C-t(-)-deleted CD37, but not the
Tyr13-Phe or the Tyr13-Phe/C-t(-) CD37. GST and GST-
SHIP(SH2) served as negative controls (Figure S2C). The p85regulatory and the p110 catalytic subunits of phosphatidylinosi-
tol 3-kinase (PI3K) have been shown to bind to phosphorylated
tyrosines within the ITAM (YxxL) motif of the FcgRIIa in macro-
phages (Cooney et al., 2001). However, it is not known whether
this association is ITAM-mediated and direct, or indirect via an
adaptor molecule. We hypothesized that the C-t portion of
CD37 negatively regulates cell death by activating a PI3K-
dependent survival signaling. Interestingly, WT but not C-t(-)
CD37 recruit p85 and p110d upon stimulation with SMIP-016,
indicating that these proteins bind to the C-t portion of CD37
(Figure 4K), consistent with an ITAM function for this domain.
The targets of PI3K family kinases include AKT, which is known
to mediate B cell proliferation and survival in response to
B cell receptor cross-ligation through phosphorylation and inac-
tivation of its downstream target GSK3b. Upon CD37 ligation
with SMIP-016, AKT and GSK3b become phosphorylated in
WT but not C-t(-) cell lines (Figure 4L). Moreover, treatment
of the WT cell line with the PI3K inhibitor LY294002, using
a concentration (10 mM) that inhibits PI3K, resulted in increased
SMIP-016-mediated cell death up to the level of the C-t(-) cell line
(Figure 4M). A similar effect is also seen in primary CLL cells,
where the combination of suboptimal doses of SMIP-016
(0.1 mg/ml) with LY294002 or with the PI3Kd inhibitor CAL-101
is more cytotoxic than any agent alone (Figures S2D and S2E).
Surprisingly, PI3Kgwas also recruited uponCD37 cross-ligation.
However, its binding was specific to the N-t portion, because it
was found to be associated to CD37 even in the absence
of the C-t domain (Figure 4N). A functional interaction between
PI3K p85/p55 and SHP1 has been shown in T lymphocytes
(Cuevas et al., 1999). This interaction was also associated with
a reduction in PI3K-mediated phosphorylation of AKT, suggest-
ing that PI3K signaling can be regulated by SHP1. Together,
these results suggest that, upon ligation of CD37, two opposing
stimuli act simultaneously on AKT and that the outcome for the
cell represents a balance between these two counteracting
pathways.
CD37 Ligation Mediates Mitochondrial Membrane
Depolarization in CLL Cells
We have previously shown that cross-ligation of CD37 by SMIP-
016 induces apoptosis of CLL cells (Zhao et al., 2007) as early
as 4 hr (data not shown) and peaked at 18 hr. Apoptosis is
induced via two main routes involving either the mitochondria
(the intrinsic pathway) or the activation of death receptors (the
extrinsic pathway). Both pathways converge to induce the
activation of caspases, although in the past years, mitochon-
drial-mediated caspase-independent forms of apoptosis have
been reported (Loeffler et al., 2001). We therefore measured
mitochondrial membrane depolarization (MMD) of CLL cells in
response to SMIP-016 using JC-1 staining. Although no MMD
was observed in trastuzumab-treated samples, (Figures 5A
and 5B), CD37 ligation resulted in 50% MMD. BIM is a critical
BH3 only domain BCL-2 family member protein responsible for
mitochondrial-induced apoptosis. Interestingly, CD37 ligation
of CLL cells resulted in consistent upregulation of BIM at both
the protein (Figure 5C) and mRNA level (Figure 5D), while the
protein level of other pro- and antiapoptotic proteins, such as
BAX, BCL2, and MCL1, remained unchanged (Figure 5C and
Figure S3).Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc. 699
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Figure 4. CD37 Possesses Dual Inhibitory and Activation Signaling Function
(A) Schematic representation of the human CD37 protein showing the mutations introduced in the cytosolic regions.
(B–D) CD37+FLAG 697WT or mutant cell lines were treated with SMIP-016+aFc. Cell death was assessed at 24 hr by annexin-V/PI assay (gray bars). Data shown
were normalized to aFc alone (B and C, n = 10; D, n = 16). Expression of CD37 was assessed by flow cytometry (red lines). RC, cells expressing a reverse
complement sequence of CD37.
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CD37 Regulates Cell Survival in B CellsCD37 Cross-Ligation Increases FoxO3a-Dependent
Transcription of BIM
CLL and a variety of other B cell lymphomas show aberrant
expression of TCL1, an oncoprotein with multiple roles in B cell
transformation, including active translocation of pAKT to the
nucleus (Figure S4A). Cytoplasmic pAKT is modest in nonstimu-
lated CLL cells, whereas nuclear pAKT is dramatically increased
(Herman et al., 2010). CD37 ligation by SMIP-016 resulted in
a decrease of CD40L-induced PI3K activity (Figure S4B). More
importantly, ligation of CD37 in CLL cells decreased basal
nuclear pAKT (Figure 6A) and CD40L-induced cytosolic pAKT
(Figure S4C). Given the observation that increased pAKT is
present in CLL cell nuclei, we hypothesized that this kinasemight
be influencing FoxO3a, a downstream targets of pAKT and
a major transcription factor regulating the expression of BIM.
As shown in Figure 6B, cross-ligation of CD37 significantly
increases the nuclear FoxO3a level. To determine whether
SMIP-016 upregulates BIM transcriptionally, a region of the
BIM promoter containing the FoxO-binding site (FHRE) was
cloned into a luciferase reporter construct (Figure 6C) and was
transiently transfected into CLL cells. As shown in Figure 6D,
BIM promoter activity was significantly induced by SMIP-016
treatment of the transfected cells. Furthermore, electrophoretic
mobility shift assay (EMSA) using an oligonucleotide sequence
derived from the BIM promoter region containing FHRE showed
increased protein binding in nuclear extract derived from CLL
cells treated with SMIP-016, but not the trastuzumab control
(Figure 6E). This binding was specific for WT but not mutant
FHRE and was prevented by using an excess of cold WT, but
notmutant, oligonucleotide probe (Figure 6F). The physical inter-
action of FoxO3a with the BIM promoter in response to SMIP-
016 was further confirmed by oligonucleotide pulldown assay
(Figure 6G) showing that SMIP-016 treatment increase the
binding of FoxO3a to the oligos containing a WT but not mutant
FHRE. Next, ChIP assay showed an increased binding of
FoxO3a to the endogenous BIM promoter in SMIP-016-treated
CLL cells (Figure 6H) but not in cells treated with irrelevant anti-
body (IgG; data not shown). Thus, the increased transcriptional
upregulation of BIM via FoxO3a following CD37 ligation by(E) Lysates from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) WT
4G10 or FLAG immunoblot.
(F) A portion of the immunoprecipitated lysates from E was treated with l-protei
were cropped out the gel.
(G) Lysates derived from WT or C-t(-) cells treated with trastuzumab+aFc (T) or
-SHP1, or 4G10 antibody, followed by immunoblot analysis with the indicated an
(H) Lysates derived fromWT, C-t(-), and Tyr13-Phe cells treated with trastuzumab+
antibody, followed by immunoblot analysis using 4G10 or anti-FLAG antibodies.
(I) Lysates derived fromWT, C-t(-), and Tyr13-Phe cells treated with trastuzumab+
-SHP1, or 4G10 antibody, followed by immunoblot analysis with the indicated an
(J) WT or C-t(-) cells were pretreated with either DMSO or herbimycin (10 mM) for
Lysates derived from these cells were immunoprecipitated with anti-SHP1 antib
(K) Lysates derived from WT and C-t(-) cells treated with trastuzumab+aFc (T) or
antibodies followed by immunoblot with the indicated antibodies. Representativ
(L) Lysates derived from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treate
antibodies.
(M) WT and C-t(-) cells were pretreated with LY294002 for 45 min before the a
measured 24 hr after treatment by annexin-V/PI (n = 15).
(N) Lysates derived from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated
followed by FLAG immunoblot (representative of two experiments). Data are rep
See also Figure S2.SMIP-016 correlates with the increased BIM protein expression
described above.
BIM Upregulation Contributes to CD37 Ligation-
Mediated Apoptosis
BIM mRNA and protein upregulation was concurrent with its
translocation to themitochondria as well as the cleavage ofmito-
chondrial BAX into p21 and p18 fragments (Figure 7A), which
was detected in the enriched mitochondrial fractions only but
not in the whole cell lysates (Figure 5C), consistent with the
observedMMD following CD37 ligation (Figure 5A). Furthermore,
BIM down-modulation by siRNA (Figure S5A) resulted in inhibi-
tion of mitochondrial depolarization, with increased intact mito-
chondria (Figure 7B) and partial reduction of SMIP-016-induced
cytotoxicity compared to the scrambled siRNA control (Fig-
ure 7C). SHP1 has been implicated in negative regulation of
neuronal survival by inhibiting phosphorylation of MAPK/ERK
and AKT and increasing BIM expression (Marsh et al., 2003).
To determine whether proximal SHP1 activation by SMIP-016
directly contributes to BIM upregulation, siRNA to SHP1 was
used. As shown in Figure 7D, SHP1-specific siRNA antagonized
BIM upregulation in CLL cells. Collectively, these studies
suggest a direct role for SHP1 in downregulating the activity of
AKT, which, in turn, inhibits FoxO3a nuclear translocation
leading to induction of BIM (Figure 7E).
SMIP-016, but not trastuzumab, also induced nuclear translo-
cation of FoxO3a (Figure S5B) and upregulation of BIM in WT
CD37+FLAG 697 cells (Figure S5C). AKT phosphorylation was
absent in the WT cell line at 18 hr (Figure S5D), corresponding
to a later time where BIM induction is seen. Moreover, the dele-
tion of Tyr13 but not Tyr274 prevented SMIP-016-induced upre-
gulation of BIM in CD37+FLAG 697 cells (Figure S5E). Together,
these results support our hypothesis that CD37 directly regu-
lates CLL cell survival.
DISCUSSION
Our study focused on elucidating the role of CD37 in the trans-
duction of apoptotic signals in transformed B cells. Analysis ofor C-t(-) cells (15 min) were immunoprecipitated with anti-FLAG, followed by
n phosphatase (l-PPase) and analyzed by 4G10 immunoblot. Irrelevant lanes
SMIP-016+aFc (S) (15 min) were immunoprecipitated using anti-SYK, -LYN,
tibodies.
aFc (T) or SMIP-016+aFc (S) (15min) were immunoprecipitated with anti-FLAG
aFc (T) or SMIP-016+aFc (S) (15 min) were immunoprecipitated using anti-LYN,
tibodies.
45 min before the addition trastuzumab+aFc (T) or SMIP-016+aFc (S) (15 min).
ody and analyzed by FLAG and SHP1 immunoblot.
SMIP-016+aFc (S) (15 min) were immunoprecipitated with anti-p85 or p110d
e of two experiments is shown.
d (S) WT and C-t(-) cells were analyzed by immunoblot using the indicated
ddition of aFc, trastuzumab+aFc (T), or SMIP-016+aFc (S) . Cell death was
(S) WT and C-t(-) cells (15 min) were immunoprecipitated using p110g antibody
resented as mean ± SD for all the relevant panels.
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Figure 5. CD37 Ligation Mediates Mitochondrial Membrane Depolarization in Primary CLL Cells
(A and B) Representative data for JC-1 staining of CLL cells treated with aFc, trastuzumab+aFc, SMIP-016+aFc, or 2-fluoro-ara-A (2-Fara) for 12hr (A). A gate was
drawn around the population with aggregated JC-1 (intact mitochondria) in untreated cells. Using this gate, the percentage of cells with intact mitochondria in
treated samples was then calculated relative to the untreated sample, set at 100% (n = 12) (B).
(C) Lysates derived from CLL cells treated as indicated were analyzed by immunoblot for expression of BIM and BAX. b-Actin was used as loading control. The
BIM level relative to the loading control was determined from five immunoblots using different patient samples.
(D) Real-time PCR analysis of BIMmRNA in trastuzumab+aFc- or SMIP-016+aFc-treated CLL cells (12 hr, n = 7). Data are represented as mean ± SD for all the
relevant panels.
See also Figure S3.
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CD37 Regulates Cell Survival in B Cellsthe CD37 protein sequence revealed three tyrosine residues in
its cytoplasmic domains with two opposing functions. One of
these residues is localized at the N-t domain within the sequence
IKYFLFV that resembles an ITIM-motif (V/L/IxYxxV/L) but with an
additional residue between the tyrosine and valine. The other two
tyrosine residues are located at the C-t domain of CD37, one of
which is in a YxxL context within a single ITAM-like signaling
motif. ITAM-like motifs were originally described in Dectin-1,702 Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc.and since then, examples of ITAM-based signaling that do not
conform precisely to the standard model are becoming increas-
ingly common (Underhill et al., 2005). Moreover, it has been
demonstrated that a synthetic peptide based on the phosphory-
lated single YxxL motif of Dectin-1 binds to SYK (Rogers et al.,
2005), suggesting that a single tyrosine phosphorylation might
be sufficient to recruit SYK. Through the use of independent
biochemical and proteomic approaches, we demonstrate that,
Cancer Cell
CD37 Regulates Cell Survival in B Cellsupon cross-ligation, CD37 is tyrosine phosphorylated directly at
two distinct tyrosine residues within the N-t (ITIM-like) and C-t
(ITAM-like) cytosolic regions. Differences in baseline level of
phosphorylation observed in primary CLL cells but not in the
CD37+FLAG 697 cell line noted in our experiments could be
attributed to in vivo stimulation of CLL cells by hitherto unidenti-
fied natural ligand for CD37. When a tyrosine in the ITIM is phos-
phorylated, it forms a docking site for the SRC homology 2 (SH2)
recognition domains of the tyrosine phosphatase SHP1.
Conversely, ITAM motifs are phosphorylated by SYK. Once
phosphorylated the pITAM motif activates SYK, which in turn
phosphorylates downstream targets that facilitate survival
signaling through PI3K.
We further investigated which complex was recruited by each
of these tyrosine domains and demonstrated, as expected,
opposing roles for these two tyrosine residues in cell survival.
We found that upon ligation of CD37, the N-t tyrosine within
the ITIM-like motif becomes phosphorylated and associates
with a specific complex of proteins, including LYN, SHP1,
SYK, and PI3Kg, whereas p85 and PI3Kd were specifically re-
cruited at the C-t domain. Taken together, these data indicate
that at least two counteracting signaling pathways originate
from ligation of CD37. One pathway acts through phosphoryla-
tion and activation of the ITIM-like motif at the N-t of CD37 by
LYN kinase, leading to SHP1 recruitment and FoxO3a-
dependent BIM upregulation and subsequent mitochondrial
depolarization and cell death. These ITIM-like and ITAM-like
functions also influence NK cell-mediated SMIP cytotoxicity,
demonstrating the potential for tumor target antigen signaling
influencing innate immune cell killing.
Our data clearly demonstrate that SHP1 is the major driving
pathway of death of CD37 ligation but do not exclude the possi-
bility that other signaling pathways, including proximal LYN and
SYK, might be involved as well. The second pathway acts
through tyrosine phosphorylation of the ITAM-like motif at the
CD37 C-t domain, with recruitment and activation of PI3K and
AKT, phosphorylation of GSK3b, and promotion of cell survival.
The binding of p85 to the phosphorylated YxxL peptide is direct,
rather than through a phosphorylated adaptor protein such as
SYK. However, these findings do not completely exclude the
involvement of an unidentified adaptor protein in p85/PI3K
recruitment. This complicated signaling network affords the
potential for approaches to augment CD37-directed therapy.
Combination treatment with SMIP-016 and the PI3Kd isoform-
specific inhibitor CAL-101 demonstrated synergy, providing
clinical rationale for combining these approaches in clinical trials.
A diagram of the signaling induced by CD37 ligation is shown
in Figure 8.
Although we showed that SMIP-016 efficacy is independent
of traditional prognostic factors in CLL, a large variability in cell
death was observed, which can be partially attributed to the
heterogeneity of CD37 expression in CLL cells and to the simulta-
neousactivationofbothpro-death (N-t) andsurvival (C-t) signaling
with SMIP-016 ligation of CD37. No mutations in the CD37
were identified among 120 patients studied (data not shown),
although this cannot exclude that CD37 or SHP1 can become
mutatedor otherwisealtered in resistant cells andwarrants further
study. Additionally, the mechanism by which BIM induction
occurs with the CD19 antibody warrants further study.In summary, we demonstrated herein (1) that CD37 can
function as a death receptor in B cells, (2) the presence of two
distinct regulatory motifs with opposing functions within the
same molecule, and (3) a direct involvement of a tetraspanin in
cell death signaling in CLL cells.EXPERIMENTAL PROCEDURES
Cell Isolation
Blood was obtained from patients with CLL as defined by 2008 IWCLL
criteria (Cheson et al., 1996; Hallek et al., 2008). All patients provided
informed consent under an Ohio State University Institutional Review Board-
approved protocol. CLL B cells were isolated and cultured as previously
described (Lapalombella et al., 2010). The purity of tumor cells in the enriched
populations was always greater than 95% as detected by dual CD19/CD3
staining.
Chemical Reagents and Cell Treatment
SMIP-016 (5 mg/ml) was produced by Emergent BioSolutions (previously
Trubion Pharmaceuticals, Seattle, WA) and is the chimeric parental molecule
of TRU-016; 2-fluoro-ara-A (2-Fara, 5 mM), rituximab (10 mg/ml), and
trastuzumab (10 mg/ml) were obtained from the OSU pharmacy; goat
anti-human IgG (aFc, at 5X antibody concentration) was purchased from
Jackson ImmunoResearch Laboratories; sodium stilbogluconate and
LY294002 were obtained from Sigma (St. Louis, MO); and FITC-labeled
annexin V and propidium iodide (PI) were purchased from BD PharMingen,
(San Diego, CA).
Protein Fractionation and Immunoblotting
Cytosolic, nuclear, and mitochondrial fractions were prepared using reagents
from Pierce (Rockford, IL) according to the manufacturer’s directions.
Immunoblots were preformed as described elsewhere (Lapalombella et al.,
2010). A detailed list of antibodies used can be found in the Supplemental
Information.
Quantitative RT-PCR
cDNA was prepared as previously described (Lapalombella et al., 2008).
Primers and probes were obtained from Applied Biosystems (Life Technolo-
gies, Carlsbad CA). The expression of BIM relative to the internal control
gene was calculated by plotting the Ct (cycle number required to reach detec-
tion threshold), and the average relative expression for each group was
determined using the comparative method (Livak and Schmittgen, 2001).
Also see Supplemental Information for additional details.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation assay was performed using the MagnaEZ
ChIP Assay Kit (Millipore) according to the manufacturer’s standard protocol
(Das et al., 2004). DNA was quantified using real-time RT-PCR with SYBR
green incorporation (Applied Biosystems). Also see Supplemental Information
for additional details.
Immunoprecipitation and Coimmunoprecipitation
Cell lysates were prepared in RIPA (for immunoprecipitation) or Co-IP buffer
(for coimmunoprecipitation). A detailed procedure is provided in Supplemental
Information.
Electrophoretic Mobility Shift Assays
EMSA procedure and sequence of the 32P-labeled BIM promoter probes are
described in Supplemental Information.
Oligonucleotide Pull-Down Assay
Oligonucleotide pull-down assays were performed as previously described
(Essafi et al., 2005). The detailed procedure is described in Supplemental
Information.Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc. 703
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Figure 6. CD37 Cross-Ligation Increases FoxO3a-Dependent Transcription of BIM
(A) Top, immunoblot of nuclear extracts derived from aFc, trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CLL cells; bottom, quantization of the
pAKT/total AKT signals in the immunoblots.
(B) Immunoblot analysis of nuclear extracts (NE) and cytoplasmic extracts (CE) from CLL cells stimulated with trastuzumab+aFc (T) or SMIP-016+aFc (S) using
FoxO3a antibody. BRG-1 and Tubulin were used to confirm quality of the separations.
(C) Schema of the Pgl3-BIM reporter construct that includes the reported FoxO3a binding site (FHRE) in the BIM promoter.
(D) Luciferase activity of CLL cells transfected with Pgl3-Basic or Pgl3-BIM reporter constructs along with the Renilla luciferase vector and treated without
or with SMIP-016+aFc (S) for 12 hr. All values were corrected for cotransfected renilla activity. Data shown are normalized to trastuzumab+aFc-treated cells
(n = 4).
(E) Nuclear extract from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CLL cells were incubated with 32P-labeled wild-type (WT) BIM probe con-
taining FoxO3a binding site and analyzed by EMSA. Representative of nine patient samples is shown.
(F) Nuclear extract fromSMIP-016+aFc-treated CLL cells were incubated with 32P-labeledwild-type (WT) ormutant (M)BIM probes in the presence or absence of
503 unlabeled wild-type or mutant BIM probes.
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Figure 7. BIM Upregulation Contributes to CD37 Ligation-Mediated Apoptosis
(A) BIM and BAX in mitochondrial extracts from CLL cells treated with trastuzumab+aFc (T) or SMIP-016+aFc (S) for 24 hr were analyzed by immunoblot.
Representative of six patient samples is shown.
(B) CLL cells were transiently transfected with BIM siRNA for 24 hr and then treated with trastuzumab+aFc (T) or SMIP-016+aFc (S) for an additional 24 hr. Cells
were then assayed for mitochondrial membrane integrity by JC-1 staining (mean ± SD; n = 4). NS, nonsense siRNA.
(C) Trastuzumab+aFc or SMIP-016+aFc induced cytotoxicity in CLL cells from (B), as measured by annexin-V/PI staining (24 hr). Each symbol represents
a different CLL patient sample; red line represents the average.
(D) BIM and SHP1 immunoblot analysis of CLL cells, from two different patients, transfected with SHP1-specific or nonsense (NS) siRNA. Two representative
samples out of a total of five are shown.
(E) Diagram depicting CD37-induced apoptosis.
See also Figures S5.
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SHP1 phosphatase activity was assessed using the malachite green
system (Upstate Biotechnology, Lake Placid, NY) according to the
manufacturer’s instruction. Detailed protocol is described in Supple-
mental Information.(G) Biotinylated double-stranded oligonucleotides containing FHRE, coupled
trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) CLL cells. Bound prot
patient samples is shown. M, mutant probe; WT, wild-type probe.
(H) Chromatin from trastuzumab+aFc-treated (T) or SMIP-016+aFc-treated (S) C
promoter (n = 4). The binding of H3 to theGAPDH promoter (H3 element) was also
Data are represented as mean ± SD for all the relevant panels.
See also Figure S4.PI3K Assay
The PI3K assay was performed on whole-cell lysates from CLL cells. The
enzyme-linked immunosorbent assay (Echelon Biosciences, Salt Lake City,
UT) was performed according to the manufacturer’s instructions as previously
described (Herman et al., 2010).to streptavidin agarose beads, were incubated with nuclear extracts from
eins were eluted and analyzed by FoxO3a immunoblot. Representative of four
LL cells (12 hr) was analyzed by ChIP assay for binding of FoxO3a to the BIM
evaluated as a control because SMIP-016 does not affectGADPH expression.
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Figure 8. Schema for SMIP-016-Induced Cytotoxicity
Upon ligation of CD37, two signaling pathways are generated, one acting through phosphorylation of the N-t ITIM-like motif of CD37 by LYN kinase, leading to
SHP1-dependent BIM upregulation and cell death. A second pathway acts through tyrosine phosphorylation of the C-t ITAM-like motif of CD37 with activation of
GSK3b and promotion of cell survival.
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Cell death was assessed using annexin-V and propidium iodide (PI) flow
cytometry-based assays (BD Biosciences, San Diego, CA) as previously
described (Lapalombella et al., 2008). Mitochondrial membrane potential
changes were assessed using the voltage-sensitive lipophilic cationic dye
5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolyl carbocyanine iodide
(JC-1; Molecular Probes, Eugene, OR) as previously described (Alinari et al.,
2011).
Transient Transfection and BIM Luciferase Activity
Luciferase assay was performed as previously described (Lapalombella et al.,
2010). The detailed protocol is described in Supplemental Information.
LC-MS/MS Studies
Briefly, after electrophoresis, gels were fixed, washed, and then stained using
Coomassie Brilliant Blue. Gels were then trypsin-digested before the peptides
were extracted and concentrated under vacuum to a final volume of 20 mL.
Peptides were separated by reversed-phase HPLC and analyzed by mass
spectrometry. The detailed procedure is described in the Supplemental
Information.706 Cancer Cell 21, 694–708, May 15, 2012 ª2012 Elsevier Inc.Retrovirus Vectors and Generation of CD37+ Cell Lines
Construction of the human CD37 FLAG in pRetro-tight-puro or pBabe-puro
and retroviral infection to establish the CD37+FLAG 697 cell line are described
in detail in Supplemental information.
Statistical Analyses
All analyses were performed by the OSU Center for Biostatistics. A detailed
description of statistical tests used is included in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2012.03.040.
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